Company
Company

Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.

Always stay updated with the free CMN Newsletter.

GenEdit

Main focus: Next-generation delivery systems

Company stage: Pre-clinical

Diseases (gene editing): Undisclosed

Genome editing tool: CRISPR

Funding stage: Private

Location: San Francisco, CA, USA

Website: https://genedit.com/

Gene editing partnerships: Sarepta Therapeutics

GenEdit develops next-generation in vivo gene delivery systems. The company raised $26M in a Series A funding round in September 2021. The technology is based on non-lipid polymer nanoparticles, and the company yet has to disclose its leading pre-clinical programmes.

Tags

HashtagGenEdit

Company: GenEdit
close
Search CRISPR Medicine